Regeneron Pharmaceuticals, Inc. rose 13.3% on Friday, October 30, 2026, on 2,851,725 shares, 4.0 times its average daily volume. Headlines around the move:
Regeneron Pharmaceuticals, Inc. (REGN:NASDAQ) closed at $927.89 on October 30, 2026, up 13.33% on the day. The stock trades 0.8% below its 52-week high of $935.34 and 56.9% above its 52-week low of $591.52. Over the past year, it gained 42.4%. Regeneron Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 30, 2025, REGN closed higher on 125 days (50%). Its best day was October 30, 2026 (+13.33%) and its worst was May 18, 2026 (-9.82%). The stock moved 10% or more in a single session 1 time.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collabor...
Find more stocks like REGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.